Amgen has reported positive top-line results from a phase 3 trial evaluating Vectibix (panitumumab) in combination with Folfiri (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients
Cellceutix has signed an agreement with Girindus America for the manufacture of Kevetrin active pharmaceutical ingredient. Terms of the agreement were not disclosed. Kevetrin is being developed to
Par Pharmaceutical has announced that the US District Court for the District of Delaware has ruled in favor of Par in its challenge of Purdue’s patents relating to
BioLife Solutions has entered into a non-exclusive distribution agreement with StemCell Technologies. Mike Rice, chairman and CEO of BioLife, said: We’re very pleased to now have our products
Ore Pharmaceuticals has reported a net loss of $2.5m, or $0.47 per share for the second quarter of 2009, a decrease when compared to a net loss of
DATATRAK International has reported a decrease in revenue by 19% or $0.41m to $1.8m for the second quarter ended June 30, 2009, compared to $2.2m for the same
GlaxoSmithKline (GSK) and Genmab have provided top-line results from an international multi-center study of Arzerra (ofatumumab) in rituximab refractory follicular non-Hodgkin’s lymphoma (NHL). Reportedly, a total of 116
GlaxoSmithKline (GSK) has signed a partnership with Oswaldo Cruz Foundation (Fiocruz) to develop and manufacture vaccines for pressing public health priorities in Brazil. The agreement will establish a
SynCo Bio Partners (SynCo) has entered into a strategic partnership with Versartis to produce Versartis’ lead drug candidate – VRS-859. Under the agreement, SynCo will further develop the
BioSante Pharmaceuticals has presented H1N1 vaccine results at the Immunotherapeutics & Vaccine Summit in Providence, RI. BioSante claims that its vaccine adjuvant – BioVant has increased the protective
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.